Reduced-intensity fludarabine/melphalan confers similar survival to busulfan/fludarabine myeloablative regimens for patients with acute myeloid leukemia and myelodysplasia

Optimal conditioning chemotherapy for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) remains uncertain. Myeloablative regimens such as fludarabine/busulfan are favored over reduced-intensity fludarabine/melphalan (Flu/Mel); however, it is not known if Flu/Mel is inferi...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Leuk Lymphoma
Autori principali: DiMaggio, Elizabeth, Zhou, Jun-Min, Caddell, Ryan, Tombleson, Rebecca, Perkins, Janelle, Anasetti, Claudio, Khimani, Farhad, Pidala, Joseph, Nishihori, Taiga, Perez, Lia, Betts, Brian, Fernandez, Hugo F., Mishra, Asmita
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2020
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7771324/
https://ncbi.nlm.nih.gov/pubmed/32133897
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2020.1731498
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi